Aldeyra Therapeutics Cash Flow - Annual (NASDAQ:ALDX)

Add to My Stocks
$7.65 $0.2 (2.55%) ALDX stock closing price Sep 17, 2018 (Closing)

The Aldeyra Therapeutics cash flow statement is one of the three reports that the company generates every quarter. The profit-loss statement shows Aldeyra Therapeutics profits, the balance sheet shows Aldeyra Therapeutics debt, and the cash flow statement reflects the liquidity and solvency of a firm. This statement reflects the company's ability to generate cash flows. Aldeyra Therapeutics saw a cash impact of $37.59M from the issuance of ALDX shares. The cash flow statement helps in the Aldeyra Therapeutics stock analysis by providing more information for evaluating changes in assets, liabilities and equities. Aldeyra Therapeutics had an outflow of $-19.22M from operating activities, $37.42M inflow due to financing activities, and $-10.19M outflow due to investing activities for 2017.

View details of Aldeyra Therapeutics cash flows for latest & last 10 financial years
show more
Fiscal year is Jan - Dec20172016201520142013
Net Income Cash Flow
-22.34M-18.69M-12.09M-5.18M13.06M
Depreciation Depletion Amortization Cash-Flow-----
Net Increase (Decrease) in Assets Liabilities-----
Cash From (used in) Discontinued Operations-----
Other Adjustments Net2.71M2.75M2.18M-0.29M-15.14M
Net Cash from (used by) Operating Activities
-19.22M-15.14M-9.31M-4.77M-1.7M
Increase (Decrease) in Prop Plant And Equipment-0.02M-0.01M-0.08M-0.01M-
Acquisition Disposition of Subsidiaires-----
Increase (Decrease) in Investments-10.17M-0.21M-12.95M--
Other Cash Inflow (Outflow) from Investment Activities-----
Net Cash from (used by) Investment Activities
-10.19M-0.22M-13.03M-0.01M-
Issuance (Purchase) of Equity Shares37.59M12.73M28.5M10.05M2.75M
Issuance (Repayment) of Debt Securities-----
Increase (Decrease) in Bank & Other Borrowings-----
Payment of Dividends & Other Cash Distributions-----
Other Cash from (used by) Financing Activities-0.16M--0.03M--0.07M
Net Cash from (used by) Financing Activities
37.42M12.73M28.46M10.05M3.74M
Effect of Exchange Rate Changes on Cash-----
Net Change in Cash & Cash Equivalents
8M-2.63M6.12M5.26M2.03M
Cash & Equivalents at Beginning of Year12.01M14.64M8.52M3.26M1.22M
Cash & Equivalents at Year End20.02M12.01M14.64M8.52M3.26M
All figures in USD. M: Millions of USD, B: Billions of USD.

Aldeyra Therapeutics stock price history provides insight into historical stock price fluctuations, and Aldeyra Therapeutics stock comparison chart enables peer comparison. Some of the key terms used in the statement of cash flows are:

  • Aldeyra Therapeutics had a Net Change in Cash and Cash Equivalents of $8M for the latest year 2017. If a firm is able to grow its cash, it is considered to be a positive signal and could lead to a jump in the Aldeyra Therapeutics stock price, albeit too much cash on hand can imply the company has no or limited avenues for growth in which to invest this cash.
  • Cash Flow from operating activities: Operating activities include the core business activities. This line item refers to the cash generated from the same and stood at a negative value of $-19.22M for ALDX.
  • Growth companies, typically most tech companies; spend heavily on investing activities and this figure stood at $-10.19M for ALDX stock. Sometimes a company might have a negative overall cash flow which may not be really bad if it is due to investment expenses. Hence it is important to check the cash flow from investment activities.
  • Cash Flow from financing activities: Financing activities include the cash that comes into a company in the form of loans or interest earned or shareholders money, as well as the cash that goes out. Aldeyra Therapeutics earned $37.42M from financing activities, in the form of repayment of loans or interest paid, dividend pay-out to shareholders etc.

Key Financial Ratios For Aldeyra Therapeutics Cash Flow